8:15
Welcome and introduction
Giorgio V. Scagliotti, MD, PhD
Session I: Epidemiology of lung cancer
8:30
Molecular epidemiology of lung cancer
Paolo Boffetta, MD
8:50
Epigenetic changes in lung cancer
Montserrat Sanchez-Cespedes, MD
9:10
Lung cancer in never smokers : A new molecular and clinical entity
Lucio Crinò, MD
9:30
Clinical case on new staging system for lung cancer
Pieter E. Postmus, MD, PhD
Session II: Keynote lecture
9:50
The c-met oncogene in human cancer
Paolo Comoglio, MD, PhD
10:20
Coffee break
Session III: Endoscopy, imaging and pathology in lung cancer
10:40
The spectrum of optics in the management of lung cancer
Thomas G. Sutedja, MD, PhD
11:00
Minimally invasive surgical techniques for the diagnosis and treatment of lung cancer
Gaetano Rocco, MD
11:20
PET in lung cancer
Otto S. Hoekstra, MD
11:40
Hot topics in diagnostic pathology
Elisabeth Brambilla, MD
12:20
Lunch symposium
The Evolving Knowledge in the Systemic Treatment of NSCLC
Supported by Eli Lilly and Company
Session IV: Thoracic radiation therapy and lung cancer
14:00
Physical and biological basis of modern radiotherapy
Paul van Houtte, MD
14:20
Combining chemotherapy and radiotherapy in stage III NSCLC
Ramaswamy Govindan, MD
14:40
Targeted therapies and thoracic radiation therapy
Umberto Ricardi, MD, PhD
15:00
Management of acute and chronic side effects of thoracic radiation therapy
Cécile Le Pechoux, MD
15:20
Clinical case of combined modality therapy
Paul van Houtte, MD
15:40
Coffee break
Session V: Targeted therapies in lung cancer: What have we learned?
16:10
Insulin-like growth factor receptor (IGF-R1) inhibitors
Luis Paz-Ares, MD, PhD
16:30
VEGF- Multiple TKIs
Martin Reck, MD
16:50
c-MET and ALK inhibitors
Ramaswamy Govindan, MD
17:10
HDAC and PARP inhibitors
Wilfried Eberhardt, MD
17:30
Targeting cancer stem cells
Ruggero De Maria, MD
17:50
Wrap up of day one
18:00
Adjourn
18:10
Satellite symposium
Gefitinib the 1st personalized therapy that has changed the paradigm for the pathway of NSCLC EGFRm+
Supported by AstraZeneca
19:10
Symposium adjourns
8:00
Welcome and introduction
Pieter E. Postmus, MD, PhD
Session VI: Supportive care in lung cancer
8:10
Role of bisphosphonates in lung cancer
Peter G. Harper, MD
8:30
Role of ESA in lung cancer: Therapeutic guidelines and clinical practice
Peter G. Harper, MD
8:50
Role of G-CSF in lung cancer: Therapeutic guidelines and clinical practice
NicholasThatcher, MB, BChir, PhD
9:10
The optimal management of lung cancer related symptoms
Kristiaan Nackaerts, MD, PhD
9:30
Clinical case on TNM staging
Pieter E. Postmus, MD, PhD
9:50
Coffee break
Session VII: Changing the treatment paradigms in lung cancer
10:10
Treatment choices in front line management of NSCLC
Giorgio V. Scagliotti, MD, PhD
10:30
Maintenance strategies in NSCLC
Silvia Novello, MD
10:50
Systemic treatment for recurrent or refractory NSCLC
Christian Manegold, MD
11:10
Lights and shadows in the systemic treatment of SCLC
Egbert F. Smit, MD, PhD
11:50
Lunch symposium
Putting evidence into practice: Optimizing outcomes for patients with NSCLC
Supported by Roche
Session VIII: Elderly and PS2 patients
13:30
Any limit to surgery for patients over 75 years old?
Walter Weder, MD
13:50
The best choice for systemic treatment in the elderly
Elisabeth Quoix, MD
14:10
Is a pharmacogenomic approach a doable strategy in the elderly?
George Simon, MD
14:30
PS2 patients: Treat or not treat?
Rogerio Lilenbaum, MD
14:50
Clinical case
Session IX: Rare thoracic tumors
15:10
Malignant thymoma
Egbert F. Smit, MD, PhD
15:30
Neuroendocrine tumors other than SCLC
Eric Lim, MD
15:50
Clinical Case on TNM staging of carcinoid
Pieter E. Postmus, MD, PhD
16:00
Adjourn
©2011 Imedex®, LLC. All rights reserved. Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.